Evidence map›Paper›PMID 40063504›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations.

Rita Pereira, Alan Mackay, Yura Grabovska, Amelia Bradley, Tabitha Bloom, James Nicoll, Delphine Boche, John Procter, Mellissa Maybury, Johanna Schagen and 32 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Rita Pereira *Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-6368-0424
Alan Mackay *Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-3323-4017
Yura Grabovska *Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-3419-2234
Amelia BradleyClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0009-0007-2030-6495
Tabitha BloomClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0009-0007-1784-8330
James NicollClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-9444-7246
Delphine BocheClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-5884-130X
John ProcterNeuropathology and Pathology Research, Royal Preston Hospital, Preston, United Kingdom.ORCID 0009-0000-5391-6416
Mellissa MayburyOncology Services Group, Queensland Children' Hospital, Brisbane, Australia.ORCID 0000-0003-1852-2061
Johanna SchagenChild Health Research Centre, The University of Queensland, Brisbane, Australia.ORCID 0000-0001-7889-8402
Liam WalkerDepartment of Cellular Pathology, Northern Care Alliance, Salford, United Kingdom.ORCID 0000-0003-3237-4253
Federico RoncaroliDepartment of Cellular Pathology, Northern Care Alliance, Salford, United Kingdom.ORCID 0000-0003-3650-5572
Konstantina KarabatsouDepartment of Neurosurgery, Manchester Centre of Clinical Neuroscience, Northern Care Alliance, Salford, United Kingdom.ORCID 0000-0001-8778-6496
Olumide OgunbiyiNeuropathology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.ORCID 0000-0001-5208-5526
Thijs van DalenNeurosurgery Department, National Hospital for Neurology and Neurosurgery, UCLH, London, United Kingdom.ORCID 0009-0000-4690-1347
Jai SidpraPaediatric Neuro Oncology, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0003-1985-5503
Sabrina RossiSabrina Rossi. Pathology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.ORCID 0000-0002-1477-8855
Evelina MielePediatric Onco-Haematology, Cell Therapy, Gene Therapies and Hematopoietic Transplant, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.ORCID 0000-0002-4747-1032
David S ZieglerChildren's Cancer Institute, Lowy Cancer Centre, UNSW Sydney, Kensington, Australia.ORCID 0000-0001-7451-7916
Zhifeng ShiNeurosurgery, Fudan University, Shanghai, China.ORCID 0000-0003-1719-0456
Thomas S JacquesGeoffrey Jefferson Brain Research Centre, Division of Neuroscience, School of Biology, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-7833-2158
Darren HargravePaediatric Neuro Oncology, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0001-8219-9807
Bassel ZebianNeurosurgery Department, King's College Hospital, London, United Kingdom.ORCID 0000-0002-4675-1550
Cristina BleilNeurosurgery Department, King's College Hospital, London, United Kingdom.ORCID 0000-0002-3845-5831
Joseph YatesDepartment of Cellular Pathology, University Hospital Southampton NHS Trust, Southampton, United Kingdom.ORCID 0000-0002-4236-2996
Emma NortonDepartment of Cellular Pathology, University Hospital Southampton NHS Trust, Southampton, United Kingdom.ORCID 0000-0003-1877-2474
Henry MandevilleDepartment of Paediatric and Teenager & Young Adult Neuro-Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.ORCID 0000-0001-6820-8578
Antonia CreakDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-9426-2989
Liam WelshDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-9150-0737
Lynley MarshallDepartment of Paediatric and Teenager & Young Adult Neuro-Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.ORCID 0000-0002-6537-2118
Fernando CarcellerDepartment of Paediatric and Teenager & Young Adult Neuro-Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-3094-3758
Sucheta J VaidyaDepartment of Paediatric and Teenager & Young Adult Neuro-Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.ORCID 0000-0003-2980-9316
Zita ReiszNeuropathology Department, King's College Hospital, London, United Kingdom.ORCID 0000-0003-4018-3844
Safa Al-SarrajNeuropathology Department, King's College Hospital, London, United Kingdom.ORCID 0000-0002-6783-3571
Angela MastronuzziPediatric Onco-Hematology, Cell Therapy, Gene Therapies and Hematopoietic Transplant, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy.ORCID 0000-0002-4408-2373
Andrea CaraiNeurosurgery Unit, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy.ORCID 0000-0002-5203-7855
Maria VinciPaediatric Cancer Genetics and Epigenetics Research Unit, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.ORCID 0000-0002-7952-6771
Kathreena M KurianUniversity of Bristol Brain Tumour Research Centre, Neuropathology, Southmead Hospital, Bristol, United Kingdom.ORCID 0000-0003-0303-3716
Ho-Keung NgChinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-2614-2213
Sebastian BrandnerDivision of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and Queen Square Institute of Neurology, London, United Kingdom.ORCID 0000-0002-9821-0342
Chris Jones *Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-8118-2296
Matthew Clarke *Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-2405-5770

Funding

Academy of Medical Sciences (The Academy of Medical Sciences) SGL028/1028British Neuropathological Society (BNS) BNS small grant awardCancer Research UK (CRUK)Pathological Society of Great Britain and Ireland JSPS CLSG 1022 01Penguins Against Cancer Fergus Scholefield Cancer Research Fund
6 · The paper itself

Abstract

purposeHigh-grade gliomas (HGG) occur in any central nervous system location and at any age. HGGs in teenagers/young adults (TYA) are understudied. This project aimed to characterize these tumors to support accurate stratification of patients. EXPERIMENTAL

design207 histone/IDH wild-type tumors from patients aged 13 to 30 years were collected. DNA methylation profiling [Illumina EPIC BeadArrays, brain tumor classifier (MNPv12.8 R package)] classified cases against reference cohorts of HGG. Calibrated scores guided characterization workflows [RNA-based ArcherDx fusion panel (n = 92), whole-exome sequencing (n = 107), and histology review).

results53.4% (n = 86) matched as pediatric-type subgroups [pedHGG_RTK1A/B/C (31.7%, n = 51, PDGFRA, CDKN2A/B, SETD2, and NF1 alterations), pedHGG_MYCN (8.1%, n = 13, MYCN/ID2 amplifications), and pedHGG_RTK2A/B (7.5%, n = 12, TP53, BCOR, ATRX, and EGFR alterations)]. Eighteen percent (n = 29) classified as adult-type subgroups [GBM_MES (15.5%, n = 25, enriched for RB1, PTEN, and NF1 alterations) and GBM_RTK1/2 (2.5%, n = 4, CDK4 amplifications)]. Twenty-three cases (14.7%) classified as novel, poorly characterized subgroups with distinct methylation profiles and molecular features [pedHGG_A/B (n = 10 6.2%), HGG_E (n = 6 3.7%), HGG_B (n = 2 1.0%), and GBM_CBM (n = 5 3.1%)] with variable histologic morphology. Eight cases (5.1%) showed hypermutator phenotypes, enriched in HGG_E, one of which was associated with constitutional mismatch repair deficiency, and their sibling, who was diagnosed with the same syndrome, was diagnosed with a tumor that classified as a pedHGG_RTK1B. HGGs that have developed on a background of previous treatment for a childhood cancer are detected in the TYA population, classifying most frequently as pedHGG_RTK1 and contributing to the poor prognosis of this subgroup. Age distribution/molecular profile comparisons using publicly available methylation/sequencing data (and from local diagnostic cohorts) for HGG_B (n = 19), GBM_CBM (n = 35), and GBM_MES_ATYP (n = 102), irrespective of age, show that HGG_B is a TYA-specific subgroup (median age 29 years) and that GBM_CBM and GBM_MES_ATYP show a peak of distribution in the TYA population but also have a wider age distribution (median age 35.7 and 50.5 years, respectively), with the latter showing distinct differences in copy-number profiles compared with older adults in the same subgroup and containing fewer chr7 gains, chr10 losses, more CDKN2A/B deletions and MET amplifications, and a worse survival compared with adult-specific GBM_MES_TYP.

conclusionsTYA HGGs comprise novel methylation subgroups with distinct methylation and molecular profiles. Accurate stratification of these patients will open opportunities to more effective treatments, including immune checkpoint, MAPK pathway, and PDGFRA inhibitors. See related commentary by Ritzmann et al., p. 3110.

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaHistonesIsocitrate DehydrogenaseAdolescentAdultDNA MethylationFemaleHumansMaleMutationNeoplasm GradingYoung AdultBiomarkers, TumorHistonesIsocitrate Dehydrogenase

Identifiers

PMID40063504
PMCPMC12314528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.